Matching-adjusted indirect comparison of bosutinib, dasatinib and nilotinib effect on survival and major cytogenetic response in treatment of second-line chronic phase chronic myeloid leukemia

Jorge E. CortesDepartment of Leukemia, MD Anderson Cancer Center, Houston, TX, USA;

Bogdan MuresanIngress-Health, Rotterdam, The Netherlands; Correspondence[email protected]

Carla MamoloPatient & Health Impact, Pfizer Inc., Groton, CT, USA;

Joseph C. CappelleriGlobal Biometrics & Data Management, Pfizer Inc., Groton, CT, USA;

Rocco J. CrescenzoWorldwide Research & Development, Pfizer Inc., Walton Oaks, UK (at the time of this research);

Yun SuPatient & Health Impact, Pfizer Inc, New York, NY, USA (at the time of this research);

Carlo Gambacorti-PasseriniDepartment of Hematology, University of Milano Bicocca, Monza, Italy;

Bart HeegIngress-Health, Rotterdam, The Netherlands;

B. Douglas SmithDepartment of Oncology, John Hopkins University School of Medicine, Baltimore, MD, USA

Your download is now in progress and you may close this window